THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in…Original Article
FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
